Pfizer Stock Price, News & Analysis (NYSE:PFE)

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer declared a quarterly dividend on Thursday, June 27th. Stockholders of record on Friday, August 2nd will be given a dividend of $0.36 per share on Tuesday, September 3rd. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date of this dividend is Thursday, August 1st. View Pfizer's Dividend History.

Pfizer declared that its Board of Directors has approved a stock repurchase plan on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.8% of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its stock is undervalued.

Pfizer Inc. (NYSE:PFE) released its quarterly earnings data on Monday, July, 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.75 by $0.05. The biopharmaceutical company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm's quarterly revenue was down 1.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.77 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Pfizer.

Pfizer will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Pfizer issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided EPS guidance of $2.76-2.86 for the period, compared to the Thomson Reuters consensus estimate of $2.91. The company issued revenue guidance of $50.5-52.5 billion, compared to the consensus revenue estimate of $53.45 billion.

17 analysts have issued 12-month price objectives for Pfizer's shares. Their forecasts range from $36.00 to $55.00. On average, they anticipate Pfizer's share price to reach $45.8750 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Pfizer.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

News coverage about PFE stock has trended somewhat negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pfizer earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Pfizer.

Pfizer saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 55,228,300 shares, a decline of 18.7% from the July 31st total of 67,951,100 shares. Based on an average trading volume of 25,340,000 shares, the short-interest ratio is currently 2.2 days. Approximately 1.0% of the company's shares are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), General Electric (GE), Intel (INTC), Exxon Mobil (XOM), Bank of America (BAC), Merck & Co., Inc. (MRK) and Walt Disney (DIS).

Pfizer's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.01%), Price T Rowe Associates Inc. MD (1.69%), Northern Trust Corp (1.37%), Bank of New York Mellon Corp (1.06%), Morgan Stanley (0.84%) and Fisher Asset Management LLC (0.79%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, Barrow Hanley Mewhinney & Strauss LLC, Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., AQR Capital Management LLC, Quest Capital Management Inc. ADV, Vanguard Group Inc. and Acadian Asset Management LLC. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Natixis, Natixis, Invesco Ltd., Thoroughbred Financial Services LLC, Railway Pension Investments Ltd, Fisher Asset Management LLC and Jensen Investment Management Inc.. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $36.69.

Pfizer has a market capitalization of $202.93 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.

The official website for Pfizer is http://www.pfizer.com/.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.